TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10925615
Drug: Ten treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ten treatments of 3 Gy delivered over two weeks
Study: 8922218
Drug: Fluid infusion
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid infusion pump pressures maintained below women's mean arterial pressures (MAPs)
Study: 8922218
Drug: Fluid infusion
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid infusion pump pressures set at random
Study: 1565267
Drug: Thymopentin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymopentin (50 mg) given three times before surgery and three times after surgery
Study: 22626675
Drug: 3.75 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 μg of antigen with half the standard dose of MF59 adjuvant
Study: 22626675
Drug: 7.5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 μg of antigen with a full dose of MF59 adjuvant
Study: 22626675
Drug: Non-adjuvanted vaccine
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjuvanted vaccine containing 15 μg of antigen
Study: 22626675
Drug: 3.75 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 μg adjuvanted formulation
Study: 22626675
Drug: 7.5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 μg adjuvanted formulation
Study: 22626675
Drug: Booster vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster vaccination with seasonal influenza vaccine
Study: 11789969
Drug: Cilostazol 100
Normalized name: cilostazol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol 100 mg bid
Study: 18166097
Drug: Periodontal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal therapy (scaling and root planing)
Study: 17149989
Drug: Caffeine supplementation
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine supplementation (201 mg of caffeine per day)
Study: 17149989
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 pills per day)
Study: 14976565
Drug: RAC4 (rabeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAC4 (rabeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 4 days)
Study: 14976565
Drug: RAC7 (rabeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAC7 (rabeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 7 days)
Study: 14976565
Drug: OAC7 (omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC7 (omeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 7 days)
Study: 16917623
Drug: Bromazepam 6
Normalized name: bromazepam 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromazepam 6 mg
Study: 1329159
Drug: Bromazepam 12
Normalized name: bromazepam 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromazepam 12 mg
Study: 29059600
Drug: 17alpha‐methyltestosterone (MT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17alpha‐methyltestosterone (MT) at 15.0 mg/kg (T3)
Study: 29059600
Drug: 17alpha‐methyltestosterone (MT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17alpha‐methyltestosterone (MT) at 30.0 mg/kg (T4)
Study: 29059600
Drug: 17alpha‐methyltestosterone (MT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17alpha‐methyltestosterone (MT) at 0.3 mg/kg (T1)
Study: 29059600
Drug: 17alpha‐methyltestosterone (MT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17alpha‐methyltestosterone (MT) at 3.0 mg/kg (T2)
Study: 29059600
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no hormone)
Study: 26574050
Drug: Exercise intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exercise intervention (60 minutes general fitness class, 40 minutes endurance training/aerobic, 20 minutes strength training and stretching/relaxation, performed at least twice per week for a minimum of 12 weeks)
Study: 10591360
Drug: ramosetron 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ramosetron 0.3 mg
Study: 22358123
Drug: ramosetron 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ramosetron 0.3 mg combined with dexamethasone 8 mg
Study: 12463731
Drug: Nateglinide (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide (120 mg, 10 min before meals for 4 days) + Warfarin (30 mg on the second day)
Study: 24142206
Drug: Warfarin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (30 mg) alone
Study: 12463731
Drug: Nateglinide +
Normalized name: Nateglinide
DrugBank: Nateglinide (DB00731)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nateglinide + Warfarin
Study: 10513507
Drug: Ibuprofen 2,400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 2,400 mg/day for 28 days
Study: 7695978
Drug: Carboplatin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (400 mg/m2 intravenous day 1) and Etoposide (100 mg/m2 intravenous days 1 to > 3)
Study: 1710750
Drug: Alfuzosin (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin (daily dose 7.5‐10 mg)
Study: 7464561
Drug: Colestipol (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestipol (30 g/day)
Study: 24382002
Drug: Romosozumab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Romosozumab (all doses)
Study: 20025373
Drug: Guided self‐change
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided self‐change (GSC) treatment in group format
Study: 20025373
Drug: Guided self‐change
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided self‐change (GSC) treatment in individual format
Study: 17434635
Drug: Oral Amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Amiodarone (600 mg in three divided doses)
Study: 17434635
Drug: Intravenous Amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Amiodarone (5 mg/kg over 30 min followed by 1000 mg over the next 24 h)
Study: 1713882
Drug: Dose-reduced induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-reduced induction therapy
Study: 24865255
Drug: Standard induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard induction therapy
Study: 25960303
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training (3-month home-based aerobic training program: 4 daily cycling sessions of 10 minutes each at 90% of heart rate at anaerobic threshold)
Study: 25960303
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (standard therapy)
Study: 12597703
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg MPH
Study: 19920784
Drug: ivabradine 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivabradine 12.5 mg/day
Study: 9169252
Drug: Low-dose pilocarpine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose pilocarpine treatment
Study: 6511134
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (2.5 g) administered immediately after the drugs
Study: 6511134
Drug: Antacid (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid (20 ml of 8.5% magnesium hydroxide)
Study: 30810400
Drug: Double trigger
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double trigger (GnRH agonist and hCG, 40 and 34 h prior to OPU)
Study: 30810400
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist trigger (GnRHag 36 h before OPU and hCG on day of OPU)
Study: 18779774
Drug: quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: quetiapine XR 600 mg/day
Study: 18779774
Drug: quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: quetiapine XR 800 mg/day
Study: 18779774
Drug: quetiapine IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: quetiapine IR 300 mg/day
Study: 18779774
Drug: quetiapine IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: quetiapine IR 600 mg/day
Study: 15967972
Drug: Liposomal lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal lidocaine 4% cream
Study: 14601012
Drug: New procedure
Approvals — FDA: no, EMA: no, PMDA: no
Description: New procedure for estimating treatment effects
Study: 14601012
Drug: Conventional procedure
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Conventional procedure for estimating treatment effects
Study: 1681265
Drug: Edmonston‐Zagreb high‐titre
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edmonston‐Zagreb high‐titre (EZ‐HT) vaccine at 5 months
Study: 1681265
Drug: Schwarz high‐titre
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schwarz high‐titre (SW‐HT) vaccine at 5 months
Study: 1681265
Drug: Placebo followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo followed by standard low‐titre Schwarz vaccine at 10 months (standard)
Study: 31097853
Drug: Bupivacaine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (5 mL of 0.25%)
Study: 21412231
Drug: Ketamine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (100 mg)
Study: 31097853
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 cc distilled water)
Study: 21576658
Drug: Dabigatran 110
Normalized name: dabigatran 110 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran 110 mg twice a day
Study: 21576658
Drug: Dabigatran 150
Normalized name: dabigatran 150 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran 150 mg twice a day
Study: 15716561
Drug: Expedited treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expedited treatment of sexual partners
Study: 15716561
Drug: Expedited treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expedited treatment of sexual partners (gonorrhea)
Study: 15716561
Drug: Expedited treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expedited treatment of sexual partners (chlamydial infection)
Study: 12881083
Drug: Vaginal dinoprostone
Normalized name: dinoprostone Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal dinoprostone 6 mg every 6 hours (max 24 mg)
Study: 12881083
Drug: Vaginal glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal glyceryl trinitrate 500 micrograms every 6 hours (max 2.5 mg)
Study: 10437864
Drug: Immunisation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunisation with paternal mononuclear cells (treatment)
Study: 8848700
Drug: 5-HT2-receptor antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5-HT2-receptor antagonist ketanserine
Study: 29611536
Drug: Medium medical
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium medical ozone (40 μg/ml)
Study: 29611536
Drug: Low medical
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low medical ozone (20 μg/ml)
Study: 29611536
Drug: High medical
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High medical ozone (60 μg/ml)
Study: 23911196
Drug: Taspoglutide 10
Normalized name: Taspoglutide
DrugBank: Taspoglutide (DB14027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taspoglutide 10 mg weekly (Taspo10)
Study: 23911196
Drug: Taspoglutide 20
Normalized name: Taspoglutide
DrugBank: Taspoglutide (DB14027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taspoglutide 20 mg weekly (Taspo20)
Study: 23911196
Drug: Exenatide 10
Normalized name: EXENATIDE 10MCG/DOSE 2.4ML 60D PEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide 10 mcg BID (Exe)
Study: 19172548
Drug: Nasal testosterone
Normalized name: testosterone Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal testosterone 7.6mg, 15.2mg, or 22.8mg (single dose)
Study: 19172548
Drug: Nasal testosterone
Normalized name: testosterone Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal testosterone 7.6mg (twice or three times a day)
Study: 19172548
Drug: Nasal testosterone
Normalized name: testosterone Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal testosterone (all doses)
Study: 9951570
Drug: Synthetic adrenocorticotropic
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic adrenocorticotropic hormone (ACTH)
Study: 2190461
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) spray 1.25 mg
Study: 2190461
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) spray 2.5 mg
Study: 2190461
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) spray 5.0 mg
Study: 378754
Drug: Colchicine 1
Normalized name: colchicine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 1 mg daily, 5 days a week
Study: 29135865
Drug: Methylprednisolone administered
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone administered intravenously before cochlear implantation
Study: 23453611
Drug: No steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No steroid administration (control group)
Study: 29135865
Drug: Steroid administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Steroid administration
Study: 21767798
Drug: Moderate to
Normalized name: GenTeal Moderate to Severe Ophthalmic Gel Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate to severe depression treatment
Study: 19209097
Drug: MenACWY-CRM (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY-CRM (2 doses at 2 and 4 months of age)
Study: 19209097
Drug: MenACWY-CRM (booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY-CRM (booster dose at 12 months)
Study: 12642956
Drug: Fixed prostheses
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed prostheses on implants (upper jaw)
Study: 12642956
Drug: Removable prostheses
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Removable prostheses on implants
Study: 10721826
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy using topically applied delta‐aminolevulinic acid
Study: 8958856
Drug: Paracetamol (PAR)
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol (PAR)
Study: 1404352
Drug: Expectation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expectation of benefit from treatment
Study: 69058
Drug: 14-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-valent pneumococcal polysaccharide vaccine
Study: 31533777
Drug: Letrozole (LTZ)
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole (LTZ) 2.5 mg/day for 3 weeks
Study: 31533777
Drug: Oral metronomic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metronomic vinorelbine (mVNB) 50 mg 3 days/week for 3 weeks
Study: 31533777
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of LTZ and mVNB
Study: 15965894
Drug: Albuterol 2.5
Normalized name: levalbuterol 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol 2.5 mg nebulized
Study: 14727987
Drug: Trimetazidine 20
Normalized name: trimetazidine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine 20 mg, 3 times daily for 1 month
Study: 9007781
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both phototherapy types
Study: 26342738
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (100 mg/day)
Study: 21655065
Drug: OAC (omeprazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC (omeprazole, amoxicillin, clarithromycin)
Study: 28601610
Drug: OACB (omeprazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: OACB (omeprazole, amoxicillin, clarithromycin, bismuth)
Study: 28601610
Drug: OA+OCM (omeprazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: OA+OCM (omeprazole, amoxicillin, metronidazole)
Study: 28601610
Drug: OA+OCMB (omeprazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: OA+OCMB (omeprazole, amoxicillin, metronidazole, bismuth)
Study: 28601610
Drug: OA+OMDB (omeprazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: OA+OMDB (omeprazole, amoxicillin, metronidazole, doxycycline, bismuth)
Study: 26385671
Drug: Pain treatment
Normalized name: ARNICA MONTANA FLOWER 10 g in 50 g / SALIX ALBA BARK 15 g in 50 g / FRANKINCENSE 10 g in 50 g TOPICAL CREAM [HOUKEA Bone Pain Treatment Cream]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain treatment protocol and education program
Study: 1332433
Drug: Interactional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactional therapy
Study: 31900486
Drug: DNA administration
Normalized name: Toxoplasma gondii DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA administration by Biojector
Study: 31241441
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy and vitamin D
Study: 29676139
Drug: Xinling Wan
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinling Wan (two pills each time, three times daily for 4 weeks)
Study: 16556147
Drug: Steroid maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid maintenance
Study: 15284215
Drug: Immunosuppressive/antibiotic treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive/antibiotic treatment (IA)
Study: 11331055
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg of conjugated equine estrogens plus 2.5 mg of medroxyprogesterone acetate in 1 tablet daily (n = 1,380)
Study: 2447789
Drug: High-protein diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein diet (2 g.kg‐1.day‐1)
Study: 2447789
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet (0.55 g.kg‐1.day‐1)
Study: 27418820
Drug: IB/SAL-HFA pMDI,
Approvals — FDA: no, EMA: no, PMDA: no
Description: IB/SAL-HFA pMDI, 20 μg qid
Study: 27418820
Drug: IB/SAL-CFC pMDI,
Approvals — FDA: no, EMA: no, PMDA: no
Description: IB/SAL-CFC pMDI, 20 μg qid
Study: 26037428
Drug: Pasireotide 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 900 μg subcutaneously twice daily for 7 days
Study: 22862906
Drug: Recapture Life
Normalized name: Life-O-Gen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recapture Life intervention (six, weekly, 90-minute online group sessions led by a psychologist)
Study: 18989993
Drug: One 800
Normalized name: metaxalone 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: One 800 mg tablet (reference)
Study: 18989993
Drug: Two 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 400 mg tablets (test)
Study: 18989993
Drug: One 800
Normalized name: metaxalone 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: One 800 mg tablet in fed conditions (test)
Study: 18989993
Drug: One 800
Normalized name: metaxalone 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: One 800 mg tablet in fasting conditions (reference)
Study: 16433404
Drug: 14% doxycycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14% doxycycline gel (DOXY)
Study: 12598265
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion of levobupivacaine 0.5%, 3 mL/h (n = 33)
Study: 12598265
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion of levobupivacaine 0.15%, 10 mL/h (n = 27)
Study: 8295811
Drug: Clarithromycin oral
Normalized name: clarithromycin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin oral suspension (7.5 mg/kg, max 500 mg, twice daily)
Study: 8295811
Drug: Cefadroxil oral
Normalized name: cefadroxil Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefadroxil oral suspension (15 mg/kg, max 1000 mg, twice daily)
Study: 8295811
Drug: Clarithromycin oral
Normalized name: clarithromycin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin oral suspension
Study: 8295811
Drug: Cefadroxil oral
Normalized name: cefadroxil Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefadroxil oral suspension
Study: 3552504
Drug: Oral colonic
Normalized name: Sus scrofa colon preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral colonic lavage solution containing sodium sulfate and polyethylene glycol
Study: 26232542
Drug: 4CMenB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4CMenB vaccine (two doses, 1-month apart)
Study: 21334621
Drug: Antichlamydial treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antichlamydial treatment
Study: 21334621
Drug: No antichlamydial
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antichlamydial treatment
Study: 17239430
Drug: Weekly topotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly topotecan 4.0 mg/m2 on days 1, 8, and 15 of a 28-day cycle
Study: 11379679
Drug: Intravenous 30
Normalized name: fat emulsion, intravenous 30% intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 30 mg ketorolac administered before tourniquet inflation
Study: 11379679
Drug: Intravenous 30
Normalized name: fat emulsion, intravenous 30% intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 30 mg ketorolac administered after tourniquet inflation